Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal dose of Campath for patients with
relapsing or refractory (failed standard therapy) non-Hodgkin's lymphoma. The study will also
evaluate the safety of the drug and whether it is effective in treating these patients.